Hospital
Chca Pearland, L.P.
Chca Pearland, L.P. was paid $6.28M by Medicaid between Sep 2020 and Dec 2024, across 51 billing codes. Its largest line is 99283, emergency room visit (moderate) — 54% of everything it billed.
33Billing provider infoCHCA PEARLAND, L.P.
PEARLAND, TX 77584
PEARLAND, TX 77584
33aNPI1609275585assigned 08/18/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.28M
24GClaims61,679
24DCodes billed51
24AFirst – last monthSep 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#27 of 109
Median peer was paid$1.15M
This provider vs. median5.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 580 | $113K | |
| 2021 | 11,121 | $1.36M | |
| 2022 | 20,836 | $2.00M | |
| 2023 | 19,775 | $1.90M | |
| 2024incomplete | 9,367 | $916K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 54% | 14,175 | 13,720 | $3.39M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 33% | 5,816 | 5,508 | $2.04M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.0% | 942 | 929 | $250K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 1,850 | 1,726 | $73K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 242 | 236 | $70K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.0% | 3,808 | 3,579 | $64K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 4,209 | 4,107 | $54K |
| 55180 | <1% | 32 | 32 | $47K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,210 | 3,929 | $44K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,440 | 2,235 | $37K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 193 | 183 | $37K |
| 85027 | <1% | 6,041 | 5,580 | $30K |
39 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,659 | $28K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,445 | $24K |
| 81003 | <1% | 4,930 | $15K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,054 | $14K |
| 80076 | <1% | 1,341 | $9K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 329 | $8K |
| 84702 | <1% | 920 | $7K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 689 | $5K |
| 84484 | <1% | 912 | $4K | |
| 87081 | <1% | 494 | $4K | |
| 54300 | <1% | 12 | $4K | |
| 83690 | <1% | 828 | $4K | |
| 81025 | <1% | 501 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 385 | $2K |
| 14040 | <1% | 12 | $2K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 14 | $2K |
| 87420 | <1% | 206 | $2K | |
| 54161 | <1% | 13 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 149 | $796.82 |
| 82248 | <1% | 206 | $594.22 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 15 | $417.82 |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 12 | $340.20 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 12 | $181.99 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 27 | $100.66 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15 | $56.59 |
| 85730 | <1% | 42 | $47.35 | |
| 85610 | <1% | 55 | $46.12 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 28 | $45.20 |
| 86900 | <1% | 27 | $26.53 | |
| 86901 | <1% | 27 | $26.53 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 19 | $17.21 |
| 85049 | <1% | 12 | $12.06 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 82 | $9.32 |
| 83735 | <1% | 14 | $9.01 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 17 | $7.46 |
| 85014 | <1% | 12 | $6.38 | |
| 85018 | <1% | 12 | $6.38 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| A9270 | Non-covered item or service | 0% | 182 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialARMOUR, JOHN (CFO)